These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 22978372)

  • 1. Are there any differences in the regulations of personalized medicine among the USA, EU and Japan?
    Shimazawa R; Ikeda M
    Br J Clin Pharmacol; 2013 May; 75(5):1365-7. PubMed ID: 22978372
    [No Abstract]   [Full Text] [Related]  

  • 2. Response to the comments from Drs Shimazawa and Ikeda.
    Shah RR; Shah DR
    Br J Clin Pharmacol; 2013 May; 75(5):1368-9. PubMed ID: 22978350
    [No Abstract]   [Full Text] [Related]  

  • 3. Institutional profile: University of Florida and Shands Hospital Personalized Medicine Program: clinical implementation of pharmacogenetics.
    Johnson JA; Elsey AR; Clare-Salzler MJ; Nessl D; Conlon M; Nelson DR
    Pharmacogenomics; 2013 May; 14(7):723-6. PubMed ID: 23651020
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dearth of clinically useful diagnostics limits growth of personalized medicine.
    Cohen J
    Expert Rev Clin Pharmacol; 2011 Sep; 4(5):527-9. PubMed ID: 22220302
    [No Abstract]   [Full Text] [Related]  

  • 5. Tabula Rasa HealthCare company profile: involvement in pharmacogenomic and personalized medicine research.
    Matos A; Dow P; Bingham JM; Michaud V; Lesko LJ; Knowlton CH; Turgeon J
    Pharmacogenomics; 2021 Aug; 22(12):731-735. PubMed ID: 34284600
    [No Abstract]   [Full Text] [Related]  

  • 6. Personalized medicine: is it a pharmacogenetic mirage?
    Shah RR; Shah DR
    Br J Clin Pharmacol; 2012 Oct; 74(4):698-721. PubMed ID: 22591598
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Personalized medicine: potential, barriers and contemporary issues.
    Sorich MJ; McKinnon RA
    Curr Drug Metab; 2012 Sep; 13(7):1000-6. PubMed ID: 22591350
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacogenomic biomarkers: validation needed for both the molecular genetic mechanism and clinical effect.
    Sadee W
    Pharmacogenomics; 2011 May; 12(5):675-80. PubMed ID: 21619429
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the Guidelines of the Clinical Pharmacogenetics Implementation Consortium and the Dutch Pharmacogenetics Working Group.
    Bank PCD; Caudle KE; Swen JJ; Gammal RS; Whirl-Carrillo M; Klein TE; Relling MV; Guchelaar HJ
    Clin Pharmacol Ther; 2018 Apr; 103(4):599-618. PubMed ID: 28994452
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Study of pharmacogenomic information in FDA-approved drug labeling to facilitate application of precision medicine.
    Mehta D; Uber R; Ingle T; Li C; Liu Z; Thakkar S; Ning B; Wu L; Yang J; Harris S; Zhou G; Xu J; Tong W; Lesko L; Fang H
    Drug Discov Today; 2020 May; 25(5):813-820. PubMed ID: 32032705
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world data in the molecular era-finding the reality in the real world.
    Dickson DJ; Pfeifer JD
    Clin Pharmacol Ther; 2016 Feb; 99(2):186-97. PubMed ID: 26565654
    [TBL] [Abstract][Full Text] [Related]  

  • 12. "Pharmacogenomics: achievements, challenges and prospects, for patients, pharmaceutical industries and healthcare systems".
    Sanoudou D
    Curr Pharm Des; 2010; 16(20):2182-3. PubMed ID: 20459384
    [No Abstract]   [Full Text] [Related]  

  • 13. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update.
    Amstutz U; Henricks LM; Offer SM; Barbarino J; Schellens JHM; Swen JJ; Klein TE; McLeod HL; Caudle KE; Diasio RB; Schwab M
    Clin Pharmacol Ther; 2018 Feb; 103(2):210-216. PubMed ID: 29152729
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of pharmacogenetics in public health and clinical health care: a SWOT analysis.
    Kapoor R; Tan-Koi WC; Teo YY
    Eur J Hum Genet; 2016 Dec; 24(12):1651-1657. PubMed ID: 27577547
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacogenomics Implementation: Considerations for Selecting a Reference Laboratory.
    Vo TT; Bell GC; Owusu Obeng A; Hicks JK; Dunnenberger HM
    Pharmacotherapy; 2017 Sep; 37(9):1014-1022. PubMed ID: 28699700
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cancer trial errors revealed.
    Samuel Reich E
    Nature; 2011 Jan; 469(7329):139-40. PubMed ID: 21228842
    [No Abstract]   [Full Text] [Related]  

  • 17. Fundamentals of Pharmacogenetics in Personalized, Precision Medicine.
    Valdes R; Yin DT
    Clin Lab Med; 2016 Sep; 36(3):447-59. PubMed ID: 27514461
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Are Evidence Standards Different for Genomic- vs. Clinical-Based Precision Medicine? A Quantitative Analysis of Individualized Warfarin Therapy.
    Dhanda DS; Guzauskas GF; Carlson JJ; Basu A; Veenstra DL
    Clin Pharmacol Ther; 2017 Nov; 102(5):805-814. PubMed ID: 28187492
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacogenetic guidelines and decision support tools for depression treatment: application to late-life.
    Chang DD; Eyreeuro HA; Abbott R; Coudreaut M; Baune BT; Shaman JA; Lavretsky H; Lenze EJ; Merrill DA; Singh AB; Mulsant BH; Reynolds CF; Müller DJ; Bousman C
    Pharmacogenomics; 2018 Nov; 19(16):1269-1284. PubMed ID: 30422065
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Personalized medicine: Special treatment.
    Eisenstein M
    Nature; 2014 Sep; 513(7517):S8-9. PubMed ID: 25208073
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.